First-generation oral antivirals against SARS-CoV-2

BACKGROUND: Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have received emergency use authorization for the treatment of mild-to-moderate COVID-19 in non-hospitalized patients who are at high risk for clinical progression. OBJECTIVES: To provide a clinical practice...

Descripción completa

Detalles Bibliográficos
Autores principales: Sendi, Parham, Razonable, Raymund R., Nelson, Sandra B., Soriano, Alex, Gandhi, Rajesh Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080050/
https://www.ncbi.nlm.nih.gov/pubmed/35545195
http://dx.doi.org/10.1016/j.cmi.2022.04.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080050/
https://www.ncbi.nlm.nih.gov/pubmed/35545195
http://dx.doi.org/10.1016/j.cmi.2022.04.015

Ejemplares similares